Envoy Medical, Inc. filed its quarterly report on Form 10-Q with the SEC on November 5, 2026, covering the fiscal quarter and nine-month period ended September 30, 2026, disclosing a net loss of $14,265 thousand for the nine months and $3,932 thousand for the third quarter.

Key Highlights

  • Net loss (nine months): $14,265 thousand for the nine months ended September 30, 2026, compared to $17,170 thousand for the same period in 2025, according to the filing.
  • Net revenues (nine months): $156 thousand for the nine months ended September 30, 2026, down from $166 thousand in the same period of 2025, as reported.
  • Cash position: Cash increased to $14,570 thousand as of September 30, 2026, from $3,739 thousand as of December 31, 2025, the filing disclosed.
  • February 2026 Offering: The company reported net proceeds of $27,782 thousand from the issuance of Class A Common Stock, pre-funded warrants, and Series A Warrants in a February 2026 offering.
  • Shares outstanding: 7,744,488 shares of Class A Common Stock were issued and outstanding as of November 5, 2026, up from 2,893,495 as of December 31, 2025.
  • Accumulated deficit: The accumulated deficit reached $331,609 thousand as of September 30, 2026, compared to $313,396 thousand as of December 31, 2025.
  • Research and development expenses (nine months): R&D costs totaled $9,851 thousand for the nine months ended September 30, 2026, versus $7,933 thousand in the prior-year period.

Envoy Medical's Financial Position and Operating Results Through September 2026

Envoy Medical, Inc. (NASDAQ:COCH), a Delaware-incorporated medical device company headquartered in White Bear Lake, Minnesota, reported a net loss of $3,932 thousand for the three months ended September 30, 2026, and a net loss of $14,265 thousand for the nine-month period, according to the filing. Net revenues remained limited at $66 thousand for the third quarter and $156 thousand for the nine months, compared to $42 thousand and $166 thousand in the respective prior-year periods. The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.

Total costs and operating expenses for the nine months ended September 30, 2026, were $17,221 thousand, with research and development representing the largest component at $9,851 thousand, followed by general and administrative expenses of $6,033 thousand, the filing stated. Cost of goods sold for the nine months was $835 thousand, resulting in an operating loss of $17,065 thousand for the period. The net loss attributable to common stockholders for the nine months, after cumulative preferred dividends of $3,948 thousand, was $18,213 thousand, or $1.97 per share basic and diluted.

The company's cash position improved substantially to $14,570 thousand from $3,739 thousand at year-end 2025, primarily reflecting the February 2026 equity offering that generated net proceeds of $27,782 thousand. Total assets as of September 30, 2026, were $19,158 thousand against total liabilities of $20,298 thousand, leaving a total stockholders' deficit of $1,531 thousand, compared to a deficit of $12,158 thousand at December 31, 2025. Private warrant liability stood at $3,467 thousand and publicly traded warrant liability at $446 thousand as of September 30, 2026, the filing noted.

What Was Disclosed

Envoy Medical filed its Form 10-Q for the quarter ended September 30, 2026, disclosing a nine-month net loss of $14,265 thousand, net revenues of $156 thousand, a cash balance of $14,570 thousand, and an accumulated deficit of $331,609 thousand, with share count rising to 7,744,488 following a February 2026 offering.